The week in health tech, explained in plain English.Get the free newsletter →
October 24, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

Arkansas Health System CIO Adds Hospital Administrator Role

James Reed, chief information officer of Conway Regional Health System in Arkansas, has been named site administrator of the system's Dardanelle Regional Medical Center, according to Becker's Hospital Review. Reed, who brings nearly 30 years of healthcare experience, will keep his CIO duties as he assumes the new operational post.

He replaces hospital President Alan Finley, who plans to retire. The dual appointment puts technology and day-to-day hospital operations under a single leader at the Dardanelle site, a structure more common at smaller and rural facilities where leadership benches are thinner.

The move fits a broader pattern: as digital systems become central to how hospitals run, CIOs are increasingly stepping into general management and operations roles rather than staying confined to IT. For Conway Regional, the arrangement consolidates accountability and signals that technology leadership and clinical operations are no longer treated as separate tracks.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.